Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02524769
Recruitment Status : Completed
First Posted : August 17, 2015
Last Update Posted : May 7, 2019
Sponsor:
Information provided by (Responsible Party):
Elizabeth Mueller, Loyola University

Brief Summary:
The medical field is beginning to adopt treatments that alter an individual's microbiome to improve patient health; however, this approach has not been adopted for treatment of lower urinary tract symptoms (LUTS). Here, the investigators propose the first step in development of such a therapy. If the investigators hypothesis is correct, the investigators could change the first line of treatment for hypoestrogenic women and develop future therapies that modulate bacteria in the bladder to improve not only LUTS but also treatment response. This could lead to the first treatment for lower urinary disorders that incorporates a person's individual microbiome.

Condition or disease Intervention/treatment Phase
Overactive Bladder Drug: conjugated estrogen Not Applicable

Detailed Description:

Overactive bladder (OAB) syndrome is characterized by the symptom complex of urinary urgency, usually with associated frequency and nocturia, with or without urgency urinary incontinence in the absence of infection or other pathology. Vaginal estrogen, a well-documented treatment for OAB in hypoestrogenic women, has been shown to improve symptoms of frequency, urgency and urgency urinary incontinence (UUI). Several theories have been proposed to explain the mechanism underlying estrogen's effect on lower urinary tract symptoms (LUTS). Investigators propose that estrogen treatment influences bacterial communities (microbiomes) in the vagina and bladder and alters urothelial and vaginal (AMPs); thereby improving OAB symptoms in hypoestrogenic women.

Long-standing medical dogma has been replaced by clear evidence that a female urinary microbiome (FUM) exists.This suggests that the FUM is a factor in lower urinary tract symptoms (LUTS) and that FUM diversity contributes to LUTS and treatment response, like the vaginal microbiome and its contribution to vaginal symptoms.

In hypoestrogenic women, the vaginal microbiome shifts from low diversity communities, commonly dominated by Lactobacillus, to more diverse communities dominated by anaerobes; this change can be reversed with estrogen treatment. Since the FUM of women with OAB includes bacteria similar to those of the vaginal microbiome (e.g. Lactobacillus, Gardnerella, and diverse anaerobes), investigators reason the FUM would respond similarly to estrogen and become less diverse. While almost nothing is known about urinary/vaginal microbiome interplay, even less is known about immune response modulation in the bladder and vagina. However, estrogen reduces the subsequent urinary tract infection (UTI) rate in hypoestrogenic women affected by recurrent UTI, and estrogen induces urothelial antimicrobial peptide (AMP) expression. Since AMPs exhibit microbicidal activity, stimulate inflammation, and facilitate epithelial barrier homeostasis, estrogen may work through AMPs as mediators to optimize microbial equilibrium.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Study Start Date : December 2015
Actual Primary Completion Date : November 2016
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
conjugated estrogen
All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
Drug: conjugated estrogen
0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
Other Name: Vaginal estrogen Premarin Cream® 0.625 mg




Primary Outcome Measures :
  1. Overactive Bladder Questionnaire (OAB-q) [ Time Frame: 12 weeks ]
    Self-report measure in which patients are asked to rate how much they have been bothered by bladder symptoms on a scale of 1 (not at all) to 6 (a very great deal). Patients are also asked to rate how much symptoms have affected their life on a scale of 1 (none of the time) to 6 (all of the time).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Overactive bladder
  • Clinical diagnosis of Postmenopausal:
  • English language skills sufficient to complete questionnaires
  • Clinical indication for vaginal estrogen use
  • Not currently receiving vaginal estrogen therapy

Exclusion Criteria:

  • Currently on systemic hormone replacement therapy (HRT) Have been on HRT within the past three months
  • Clinical diagnosis of estrogen dependent malignancies
  • Allergy to local estrogen therapy
  • Insufficient language skills to complete study questionnaires
  • Women with active, urinary tract infection
  • Received antibiotics within the past two weeks
  • Clinical diagnosis of stage 3 or 4 pelvic organ prolapse
  • Patient unwilling to use vaginal estrogen preparation
  • Currently on anticholinergic medication Have received anticholinergic medication within the past three months
  • Previously failed two medications for treatment of OAB Previously received intra-vesicle botulinum toxin injections Previously had posterior tibial nerve stimulation Previously had implantation of sacral neuromodulator
  • Patients wishing to start anticholinergic medication at the initial encounter
  • Undiagnosed abnormal genital bleeding
  • Clinical diagnosis of deep vein thrombosis (DVT) Clinical diagnosis of pulmonary embolism (PE)
  • Clinical diagnosis of arterial thromboembolic disease
  • Clinical diagnosis of liver dysfunction or disease
  • Clinical diagnosis of protein C, protein S or antithrombin or deficiency other known thrombophilic disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02524769


Locations
Layout table for location information
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
Sponsors and Collaborators
Loyola University
Investigators
Layout table for investigator information
Principal Investigator: Cynthia Brincat, MD Loyola University

Publications:

Layout table for additonal information
Responsible Party: Elizabeth Mueller, M.D. PhD, Loyola University
ClinicalTrials.gov Identifier: NCT02524769     History of Changes
Other Study ID Numbers: 207152
First Posted: August 17, 2015    Key Record Dates
Last Update Posted: May 7, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Elizabeth Mueller, Loyola University:
Urge Urinary Incontinence
Urinary Incontinence

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Anti-Bacterial Agents
Estrogens
Estrogens, Conjugated (USP)
Anti-Infective Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs